Baculovirus Display of Single Chain Antibody (scFv) Using a Novel Signal Peptide

Overview

Journal BMC Biotechnol

Publisher Biomed Central

Specialty Biotechnology

Date 2010 Nov 25

PMID 21092083

Citations 6

Authors

Kuntida Kitidee

Sawitree Nangola

Gaelle Gonzalez

Pierre Boulanger

Chatchai Tayapiwatana

Saw-See Hong

Affiliations

Soon will be listed here.

Abstract

Background: Cells permissive to virus can become refractory to viral replication upon intracellular expression of single chain fragment variable (scFv) antibodies directed towards viral structural or regulatory proteins, or virus-coded enzymes. For example, an intrabody derived from MH-SVM33, a monoclonal antibody against a conserved C-terminal epitope of the HIV-1 matrix protein (MAp17), was found to exert an inhibitory effect on HIV-1 replication.

Results: Two versions of MH-SVM33-derived scFv were constructed in recombinant baculoviruses (BVs) and expressed in BV-infected Sf9 cells, N-myristoylation-competent scFvG2/p17 and N-myristoylation-incompetent scFvE2/p17 protein, both carrying a C-terminal HA tag. ScFvG2/p17 expression resulted in an insoluble, membrane-associated protein, whereas scFvE2/p17 was recovered in both soluble and membrane-incorporated forms. When coexpressed with the HIV-1 Pr55Gag precursor, scFvG2/p17 and scFvE2/p17 did not show any detectable negative effect on virus-like particle (VLP) assembly and egress, and both failed to be encapsidated in VLP. However, soluble scFvE2/p17 isolated from Sf9 cell lysates was capable of binding to its specific antigen, in the form of a synthetic p17 peptide or as Gag polyprotein-embedded epitope. Significant amounts of scFvE2/p17 were released in the extracellular medium of BV-infected cells in high-molecular weight, pelletable form. This particulate form corresponded to BV particles displaying scFvE2/p17 molecules, inserted into the BV envelope via the scFv N-terminal region. The BV-displayed scFvE2/p17 molecules were found to be immunologically functional, as they reacted with the C-terminal epitope of MAp17. Fusion of the N-terminal 18 amino acid residues from the scFvE2/p17 sequence (N18E2) to another scFv recognizing CD147 (scFv-M6-1B9) conferred the property of BV-display to the resulting chimeric scFv-N18E2/M6.

Conclusion: Expression of scFvE2/p17 in insect cells using a BV vector resulted in baculoviral progeny displaying scFvE2/p17. The function required for BV envelope incorporation was carried by the N-terminal octadecapeptide of scFvE2/p17, which acted as a signal peptide for BV display. Fusion of this peptide to the N-terminus of scFv molecules of interest could be applied as a general method for BV-display of scFv in a GP64- and VSV-G-independent manner.

Citing Articles

Baculovirus as a Tool for Gene Delivery and Gene Therapy.

Ono C, Okamoto T, Abe T, Matsuura Y Viruses. 2018; 10(9).

PMID: 30235841 PMC: 6164903. DOI: 10.3390/v10090510.

Baculovirus nucleocapsid aggregation (MNPV vs SNPV): an evolutionary strategy, or a product of replication conditions?.

Rohrmann G Virus Genes. 2014; 49(3):351-7.

PMID: 25224849 DOI: 10.1007/s11262-014-1113-5.

Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex.

Praditwongwan W, Chuankhayan P, Saoin S, Wisitponchai T, Lee V, Nangola S J Comput Aided Mol Des. 2014; 28(8):869-84.

PMID: 24997121 DOI: 10.1007/s10822-014-9772-9.

Baculovirus as a vaccine vector.

Lu H, Chen Y, Liu H Bioengineered. 2012; 3(5):271-4.

PMID: 22705893 PMC: 3477694. DOI: 10.4161/bioe.20679.

Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein.

Nangola S, Urvoas A, Valerio-Lepiniec M, Khamaikawin W, Sakkhachornphop S, Hong S Retrovirology. 2012; 9:17.

PMID: 22348230 PMC: 3308923. DOI: 10.1186/1742-4690-9-17.

References

Wilk T, Gross I, Gowen B, Rutten T, de HAAS F, Welker R . Organization of immature human immunodeficiency virus type 1. J Virol. 2001; 75(2):759-71. PMC: 113972. DOI: 10.1128/JVI.75.2.759-771.2001. View

Chapple S, Jones I . Non-polar distribution of green fluorescent protein on the surface of Autographa californica nucleopolyhedrovirus using a heterologous membrane anchor. J Biotechnol. 2002; 95(3):269-75. DOI: 10.1016/s0168-1656(02)00023-8. View

Ojala K, Koski J, Ernst W, Grabherr R, Jones I, Oker-Blom C . Improved display of synthetic IgG-binding domains on the baculovirus surface. Technol Cancer Res Treat. 2004; 3(1):77-84. DOI: 10.1177/153303460400300109. View

Yoon Y, Kwon H, Hwang K, Choi E, Hong B, Kim D . Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis. 2005; 180(1):37-44. DOI: 10.1016/j.atherosclerosis.2004.11.021. View

LeDuc P, Whiteley E, Bao G, Betenbaugh M . Investigating the secretory pathway of the baculovirus-insect cell system using a secretory green fluorescent protein. Biotechnol Prog. 2000; 16(5):716-23. DOI: 10.1021/bp0001112. View

Marasco W . Intrabodies as antiviral agents. Curr Top Microbiol Immunol. 2001; 260:247-70. DOI: 10.1007/978-3-662-05783-4_13. View

Paillard F . Intrabodies to human immunodeficiency virus type 1. Hum Gene Ther. 1999; 10(9):1425-7. DOI: 10.1089/10430349950017752. View

Peipp M, Saul D, Barbin K, Bruenke J, Zunino S, Niederweis M . Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications. J Immunol Methods. 2004; 285(2):265-80. DOI: 10.1016/j.jim.2003.12.001. View

Royer M, Cerutti M, Gay B, Hong S, Devauchelle G, BOULANGER P . Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. Virology. 1991; 184(1):417-22. DOI: 10.1016/0042-6822(91)90861-5. View

10.

Possee R . Baculoviruses as expression vectors. Curr Opin Biotechnol. 1997; 8(5):569-72. DOI: 10.1016/s0958-1669(97)80030-4. View

11.

Belyakov I, Berzofsky J . Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity. 2004; 20(3):247-53. DOI: 10.1016/s1074-7613(04)00053-6. View

12.

Tewari D, Goldstein S, Notkins A, Zhou P . cDNA encoding a single-chain antibody to HIV p17 with cytoplasmic or nuclear retention signals inhibits HIV-1 replication. J Immunol. 1998; 161(5):2642-7. View

13.

BOULANGER P, Jones I . Use of heterologous expression systems to study retroviral morphogenesis. Curr Top Microbiol Immunol. 1996; 214:237-60. DOI: 10.1007/978-3-642-80145-7_8. View

14.

Marasco W, LaVecchio J, Winkler A . Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Methods. 2000; 231(1-2):223-38. DOI: 10.1016/s0022-1759(99)00159-3. View

15.

Marasco W, Sui J . The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007; 25(12):1421-34. PMC: 7097443. DOI: 10.1038/nbt1363. View

16.

Intasai N, Tragoolpua K, Pingmuang P, Khunkaewla P, Moonsom S, Kasinrerk W . Potent inhibition of OKT3-induced T cell proliferation and suppression of CD147 cell surface expression in HeLa cells by scFv-M6-1B9. Immunobiology. 2009; 214(6):410-21. DOI: 10.1016/j.imbio.2008.12.006. View

17.

Han Z, Bi X, Qin W, He H, Dai Q, Zou J . CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res. 2008; 15(3):369-74. DOI: 10.1007/s12253-008-9131-z. View

18.

Goncalves J, Silva F, Freitas-Vieira A, Santa-Marta M, Malho R, Yang X . Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J Biol Chem. 2002; 277(35):32036-45. DOI: 10.1074/jbc.M201906200. View

19.

Marasco W, Haseltine W, Chen S . Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci U S A. 1993; 90(16):7889-93. PMC: 47248. DOI: 10.1073/pnas.90.16.7889. View

20.

Kost T, Condreay J, Jarvis D . Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol. 2005; 23(5):567-75. PMC: 3610534. DOI: 10.1038/nbt1095. View